PMD10 - Sensor Augmented Pum vs Multiple Daily Injections in Very Uncontrolled Diabetes Patients: Cost Model for Hypoglycemic Events, Imss Perspective

Abstract

estimate through mathematical projections the budget impact between multiple daily injections vs Sensor-Augmented Pump on DT1 patients, considering the frequency of severe hypoglycemic events for both alternatives from the IMSS perspective. Nowadays the Mexican Institute of Social Security covers almost half of the Mexican population, that is the reason why the institution must consider alternatives that bring not only effectiveness, instead "value for money" due to cost cuttings and containment issues experienced during the last years. the cost model considered population covered by the Mexican Institute of Social Security (IMSS), in this sense the target population (base case scenario) was chosen based on those patients with DT1 diagnosed and treated, in order to model the budget impact with and without the intervention. We conducted a pragmatic literature review and treatment comparison to find out hypoglycemic events frequency (event rate and event/patient/year). The time horizon was 12 months and the model only considered the medical direct costs. after split the population (based on coverage pop at IMSS, very uncontrolled patients, diagnosed and treated), the cost model considered 40,439 DT1 patients. Without intervention, it was modelled 15,468 hypoglycemic events ($6.9 million dollars. Every treatment scenario was weighted according to literature review inputs). With intervention on base case scenario and best case (77.81% and 90.24% reduction on severe events) the frequency of severe events were 3,432 and 1,509, respectively (which it means a total costs that oscillate between $1.5 million and $675k dollars) The savings due to intervention (SAP) were described between $5.4 to 6.2 million of dollars. The analysis just account for those avoided acute events, we did not simulate those mid-term or long-term complications avoided neither indirect costs, items that could increase the effect size and costs savings due to SAP therapy on very uncontrolled DT1 patients.